Literature DB >> 26207872

Persistence of the benefit of an antioxidant therapy in children and teenagers with Down syndrome.

Eduardo Benedetti Parisotto1, Andréia Gonçalves Giaretta2, Ariane Zamoner3, Emilia Addison Machado Moreira4, Tânia Silvia Fröde5, Rozangela Curi Pedrosa3, Danilo Wilhelm Filho6.   

Abstract

This study examined the effect of an antioxidant intervention in biomarkers of inflammation and oxidative stress (OS) in the blood of Down syndrome (DS) children and teenagers during four different stages. A control group was composed by healthy children (n=18), assessed once, and a Down group composed by DS patients (n=21) assessed at the basal period (t0), as well as after 6 months of antioxidant supplementation (t1), after 12 months (after interruption of the antioxidant intervention for 6 months) (t2), and again after further 6 months of antioxidant supplementation (t3). Biomarkers of inflammation (myeloperoxidase activity - MPO and levels of IL-1β and TNF-α) and OS (thiobarbituric acid reactive substances - TBARS, protein carbonyls - PC), reduced glutathione (GSH), uric acid (UA) and vitamin E levels, as well as antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST) and gamma-glutamyltransferase (GGT) activities, were measured after each period. After the antioxidant supplementation, the activities of SOD, CAT, GPx, GR, GGT and MPO were downregulated, while TBARS contents were strongly decreased, the contents of GSH and vitamin E were significantly increased, and no changes in G6PD and GST activity as well as in UA and PC levels were detected. After the interruption of the antioxidant therapy for 6 months, DS patients showed elevated GPx and GGT activities and also elevated UA and TBARS levels. No changes in SOD, CAT, GR, GST, G6PD and MPO activities as well as in GSH, vitamin E, PC, TNF-α and IL-1β levels were detected. The results showed that the antioxidant intervention persistently attenuated the systemic oxidative damage in DS patients even after a relatively long period of cessation of the antioxidant intervention.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antioxidant therapy; Down syndrome; Oxidative stress; Persistence effect; Reactive oxygen species

Mesh:

Substances:

Year:  2015        PMID: 26207872     DOI: 10.1016/j.ridd.2015.07.010

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  9 in total

1.  Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome.

Authors:  Eduardo B Parisotto; Verónica Vidal; Susana García-Cerro; Sara Lantigua; Danilo Wilhelm Filho; Emilio J Sanchez-Barceló; Carmen Martínez-Cué; Noemí Rueda
Journal:  Neurochem Res       Date:  2016-07-23       Impact factor: 3.996

2.  Enzymatic activity induction of GST-family isoenzymes from pesticide mixture used in floriculture.

Authors:  Fernando Mejia-Sanchez; Laura Patricia Montenegro-Morales; Julieta Castillo-Cadena
Journal:  Environ Sci Pollut Res Int       Date:  2017-10-19       Impact factor: 4.223

Review 3.  Systematic review and meta-analysis shows a specific micronutrient profile in people with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium.

Authors:  Amene Saghazadeh; Maryam Mahmoudi; Atefeh Dehghani Ashkezari; Nooshin Oliaie Rezaie; Nima Rezaei
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

4.  Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis.

Authors:  Yan Zhang; Meng Che; Jing Yuan; Yun Yu; Chang Cao; Xiao-Yan Qin; Yong Cheng
Journal:  Oncotarget       Date:  2017-09-19

Review 5.  Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome.

Authors:  Laszlo Pecze; Elisa B Randi; Csaba Szabo
Journal:  Mol Med       Date:  2020-11-09       Impact factor: 6.354

Review 6.  Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules.

Authors:  Chiara Lanzillotta; Fabio Di Domenico
Journal:  Biomolecules       Date:  2021-02-11

7.  Characterization of oxidative stress in animal model of neonatal hypoxia.

Authors:  Liliane de Mello Santos Bochenek; Eduardo Benedetti Parisotto; Evelyn de Andrade Salomão; Maria José Martins Maldonado; Iandara Schettert Silva
Journal:  Acta Cir Bras       Date:  2021-12-17       Impact factor: 1.388

8.  Systemic oxidative stress in children with cystic fibrosis with bacterial infection including Pseudomonas Aeruginosa.

Authors:  Gabriela Datsch Bennemann; Emilia Addison Machado Moreira; Leticia Cristina Radin Pereira; Maiara Brusco de Freitas; Diane de Oliveira; Julia Carvalho Ventura; Eduardo Benedetti Parisotto; Yara Maria Franco Moreno; Erasmo Benicio Santos Moraes Trindade; Eliana Barbosa; Norberto Ludwig Neto; Danilo Wilhelm Filho
Journal:  Clin Respir J       Date:  2022-06-26       Impact factor: 1.761

Review 9.  Peripheral Oxidation Markers in Down Syndrome Patients: The Better and the Worse.

Authors:  Dominik Szwajgier; Ewa Baranowska-Wójcik; Joanna Grzelczyk; Wioletta Żukiewicz-Sobczak
Journal:  Dis Markers       Date:  2021-06-28       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.